For patients with HFPEF and other underlying comorbidities ... maximum oxygen consumption <85% of normal value, EF ≥40% with diastolic dysfunction evidence on echocardiogram, exercise for ...

Management of HFPEF still focuses on optimally managing ... maximum oxygen consumption <85% of normal value, EF ≥40% with diastolic dysfunction evidence on echocardiogram, exercise for ≥3 ...

No randomized controlled trial has yet demonstrated a statistically significant reduction in mortality in HFmrEF or HFpEF, in contrast to HF with reduced EF (HFrEF), the researchers noted in a ...

HFpEF (EF ≥40%) was significantly associated with inadequate FI and the primary outcome (HR 4.95; 95% CI 1.71 to 14.36; p=0.003), whereas HFrEF (EF <40%) was not associated with FI (HR 0.77; 95% CI ...

HFpEF patients were characterized by a high prevalence of left ... which documented benefit from sacubitril/valsartan among patients with HF with reduced EF. Lu H, Claggett BL, Packer M, et al.

Heart failure with preserved ejection fraction (HFpEF) will be taken as those with ejection fraction of 50% or greater, while those with EF of 40% or less will be taken as heart failure with reduced ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

FINEARTS-HF, she said, “also answers the question definitively” about whether MRAs reduce the risk of cardiovascular death or heart failure events in those with HFmrEF/HFpEF. “We know from other ...

For patients with heart failure with preserved ejection fraction, or HFpEF, the heart muscle contracts properly but the ventricles don’t relax, causing diminished blood flow. Obesity could be a ...

Researchers combined data on nearly 4,000 patients across four trials who had heart failure with preserved ejection fraction (or HFpEF) and found that 5.4% of those treated with Wegovy experienced ...

Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with ...

Medera Inc. is a clinical-stage biopharmaceutical company, focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation gene- and cell-based approaches in ...